Completed research
The following list shows an overview of completed research projects, using SHM's data. The list is filtered to show only those projects which are made available to the general public.
| SHM no. |
Project title and publication details |
Authors |
| I15142 |
Use of regular outpatient medication in HIV/HCV co-infected patients in the Netherlands |
Smolders E., Buger D, Arends J, van der Valk M, Brinkman K, Rijnders B, Dofferhof T. |
| I15022 |
Community viral load as a tool for HIV surveillance in the Netherlands and South Africa |
E. Op de Coul, R. Bolijn, J. Heijne, A. van Sighem, M. Kretzschmar, HIV Behandelaar |
| I14157 |
Overlap between HIV and HCV networks among MSM with HIV/HCV coinfection |
J. Vanhommerig, J. Schinkel, D. Bezemer, T. van de laar, A. van Sighem, C. Smit, M. Prins |
| I14144 |
Geographical Information System to determine high prevalence aeras of targeted screening and early case-finding |
I. Joore, J. van Bergen, E. op de Coul, A. van Sighem, J. Prins, S. Geerlings |
| I14096 |
Primary and recurrent venous thromboembolism in Hiv-1 (PREDICT study) |
J. Borjas-Howard, B.J.A. Rijnders, C. Rokx, Y.I.G.V. Tichelaar, A. Verbon, K. Meijer |
| I14201 |
Failure of donor selection: what can the virus of the donor tell us? Paper: Phylogenetic evidence for underreporting of male-to-male sex among human immunodeficiency virus-infected donors in the Netherlands and Flanders |
T. van de Laar, D. Bezemer, H. Zaaijer, P. van Switten, A. van Sighem, E. Vlaas, V. Compernolle, G. Vanderwalle, A. de Smet, K. van Laethem, A. Vandamme |
| I13061 |
Factors associated with time to HIV RNA suppression in women with HIV infection starting antiretroviral treatment during pregnancy Paper: Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women |
T. Mudrikova, W. van Snippenburg, A. Wensing, J. Nellen, M. Godfried, C. Smit |
| I13059 |
Clinical, Immunological, Virological and Social outcomes of cART treated HIV infected children after transition into adult health care services (CLIVIA study) Paper: Virological and social outcomes of HIV-infected adolescents and young adults in the Netherlands before and after transition to adult care |
A.M. Weijsenfeld, M. Mutschelknauss, F.J.B. Nellen, C. Smit, D. Pajkrt, L. van der Knaap, H. de Jonge, N. Nauta, R.Strik-Albers |
| I14082 |
HIV testing and couselling in eneral practices in the Netherlands Paper: Missed opportunities to offer HIV tests to high-risk groups during general practitioners STI-related consultations: an observational study |
E. Op de Coul, I. van den Boek, I. Joore, D. Reukers, J. van Bergen, A. van Sighem |
| I13153 |
Factors associated with late diagnosis of HIV in the Netherlands |
E. Op de Coul, A. van Sighem, K. Brinkman, M. van der Ende, S. Geerligns, P. Reiss |
| I13087 |
Dutch protease for hepatitis C in HIV-infected patients - study (DECIDE-study) Paper: Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients |
J.E. Arends, A.I.M. Hoepelman, K.Brinkman, J. van der Meer, I. van de Ende, C. Richter, E.F. Schippers, D. de Vries-Sluijs, J. Schinkel, C. Smit |
| I13018 |
I13018 Efficacy of lamivudine compared to emtricitabine in nevirapine and efavirenz based antiretroviral therapy: an observational retrospective cohort study Date of approval: 3 June 2013 Paper: Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort |
Rokx C, Rijnders B, Verbon A, van de Vijver D |
| I12106 |
Differences between HIV-1-infected children in the Netherlands from different countries of origin |
Pajkrt D, van Bilsen W, Cohen S |
| I12001 |
Low mother-to-child transmission rate of hepatitis C in cART-treated HIV-1 infected mothers |
Van de Ende M, Snijdewind I, Smit C, Schutten M, Hartwig N, de Wolf F |
| I11072 | Virologic response after initiation of triple-class antiretroviral therapy in patients with primary and chronic HIV Infection Date of approval: 6 July 2011 Paper: Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection. Grijsen ML, Holman R, Wit FW, Gras L, Lowe SH, Brinkman K, de Wolf F, Prins JM. AIDS. 2012 Sep 24;26(15):1974-7. Abstract |
M. Grijsen |
| I11010 | The effect of Maraviroc on serum markers Date of approval: 9 February 2011 Poster: Maraviroc Intensification in Patients with Suboptimal Immunological Recovery Despite Virological Suppressive HAART: a 48-week, Placebo-controlled Trial van Lelyveld S. Poster at NCHIV 2013 (no. 55) |
V. van der Pas |
| I10270 | Predictors for Pneumocystis jirovecii pneumonia (PJP) during HAART era in ATHENA cohort Date of approval: 24 March 2011 Paper: Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands; host or environmental factors? Schoffelen AF, van Lelyveld SF, Barth RE, Gras L, de Wolf F, Netea MG, Hoepelman AI. AIDS. 2012 Dec 31. [Epub ahead of print] Abstract |
S. van Lelyveld A. Hoepelman L. Gras S. Hermans |
| I10053 | Schatting van de onderrapportage van HIV geinfecteerde TBC patienten in Nederland Date of approval: 13 January 2011 |
F. van Leth, F. Wit e.a. |
| I05511 | Influence of HIV-1 co-receptor usage on the clinical course of infection under HAART and the outcome of antiretroviral therapy Date of approval: October 2005 |
H. Schuitemaker, K. Brinkman |
| I09050 | Contribution of multiple genetic variants, previously validated in genome-wide analyses, to acute coronary artery events in HIV-infected individuals-an international collaborative study Date of approval: April 2009 Paper: Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26. Abstract |
H. Schuitemaker, P. Reiss. |
| I08196 | The effect of Radio Therapy on CD4 cell count in HIV-infected patients Date of approval: March 2008 Paper: Prolonged decrease of CD4+ T lymphocytes in HIV-1 infected patients after radiotherapy for a solid tumor Sankatsing SUC, Hillebregt MMJ, Gras L, Brinkman K, van der Ende M, de Wolf F, Stalpers LJA, Prins JM J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):546-9. Abstract |
S.U.C. Sankatsing, J.M. Prins, A. Verbon, L.A. Gras. |
| I11095 |
Quadruple versus triple antiretroviral therapy |
Grijsen M |
| I09071 |
The impact of the presence of TAM's including revertants on the compostion and the efficacy of a first line HAART regimen |
van der Ende M.E., el Barzouhi A., Schutten M., Rijnders B.J.A., e.a. |
| I0000 |
Role of host genetics in the clinical course of HIV infection |
Schuitemaker H., van 't Wout A., de Wolf F. |
| I06208 |
Long-term quality of life and |
Sprangers M.A.G., Nieuwkerk P.T. |
| I07010 | Efficacy and safety of dose reductions of efavirenz as part of therapeutic drug monitoring Date of Approval: January 22, 2007 Paper: Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):240-5. Abstract |
van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW. |
| I07058 | Nevirapine, nelfinavir and other protease inhibitor side effects during pregnancy Paper: Steady-state nevirapine plasma concentrations are influenced by pregnancy. Nellen JF, Damming M, Godfried MH, Boer K, van der Ende ME, Burger DM, de Wolf F, Wit FW, Prins JM. HIV Med. 2008 Apr;9(4):234-8. Abstract |
van der Ende ME, Boer K, Godfried MH, Nellen FJ. |
| I05011 | Atazanavir switch study Date of Approval: October 10, 2004 Paper: Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P. HIV Clinical Trials. 2009 May-June;10(3):168-80. Abstract |
van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P. |
| I07020 | A longitudinal inter-cohort study on antiretroviral combinations including nevirapine Date of Approval: January 23, 2007 Paper: Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Antivir Ther. 2009;14(7):931-8. Abstract |
Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. |
| I04031 | Heterosexual HIV transmission among migrants originating from Surinam, the Netherlands Antilles and Aruba: the role of traveling to the country of origin Date of Approval: July 08, 2004 Paper: Migrants travelling to their country of origin: a bridge population for HIV transmission? Kramer MA, van Veen MG, de Coul EL, Geskus RB, Coutinho RA, van de Laar MJ, Prins M. Sex Transm Infect. 2008 Dec;84(7):554-5. Abstract Paper: HIV Transmission Patterns among The Netherlands, Suriname, and The Netherlands Antilles: A Molecular Epidemiological Study. Kramer MA, Cornelissen M, Paraskevis D, Prins M, Coutinho RA, van Sighem AI, Sabajo L, Duits AJ, Winkel CN, Prins JM, van der Ende ME, Kauffmann RH, Op de Coul EL. AIDS Res Hum Retroviruses. 2010 Oct 7. [Epub ahead of print] Abstract |
Prins M, Op de Coul E, Kramer MA, Cornelissen MI, van Sighem A, Sabajo LOA, Duits AJ, Prins JM, Kauffman RH, van der Ende ME. |
| I07087 | Combined use of lopinavir/ritonavir and rifampin in HIV patients coinfected with tuberculosis (TB) Date of Approval: March 23, 2007 Paper: Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM. AIDS 2009, 23:863–867. Abstract |
Burger DM, L’homme RF. |
| I04046 | Predictors of frequencies; key characteristics of observational data obtained from HIV-infected patients participating in the national cohort on AIDS therapy evaluation in The Netherlands (ATHENA) Date of Approval: July 8, 2004. Paper: The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. Am J Epidemiol 2006 Apr 1; 163(7): 676-83. Abstract |
Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. |
| I04044 | Semi-parametric accelerated failure time regression analysis with application to interval censored HIV/AIDS data Date of Approval: July 8, 2004. Paper: Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data. Xue H, Lam KF, Cowling BJ, de Wolf F. Stat Med 2006 Nov 30; 25(22): 3850-63. Abstract |
Xue H, Lam KF, Cowling BJ, de Wolf F. |
| I04016 | The Genotypic Inhibitory Quotient (GIQ) for Lopinavir Date of Approval: April 22, 2004. Paper: The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM. AIDS 2006 Apr 24;20(7):1069-1071. Abstract |
Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM. |
| I07903 | Antiretroviral treatment of primary HIV infection Date of Approval: April 15, 2003 This research is continued through a new research proposal with the following title ‘Primo-SHM’ (I08044) which started as from February 2008.I08044 |
Prins JM, Steingrover R, Kroon FP, van Valkengoed I. |
| I07015 | Nevirapine hypersensitivity reactions study, Paper: Discontinuation of Nevirapine Due to Hypersensitivity Reactions in Patients with Prior Treatment-experience Compared to Treatment-naïve Patients: The ATHENA Cohort Study. Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P. Clin Infect Dis. 2008 Mar 15;46(6):933-40. Abstract |
Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P. |
| I08203 | Transmission of antiretroviral drug resistant HIV-1 and HIV-1 subtypes in recently infected and therapy-naive individuals in the Netherlands Date of approval: Oct 21, 2004 Paper: Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration. Antiviral Therapy 2006; 11: 173-17. Abstract Paper: Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, Berkhout B, Coutinho R, Back NK. Municipal Health Service Amsterdam, The Netherlands. AIDS. 2004 Jul 23;18(11):1571-7. Paper |
Coutinho RA, de Wolf F, Prins M. |
| I17603 | Clinical, immunological and virological parameters in a cohort of HIV-2 infected patients in the Netherlands on or off therapy with different antiretroviral regimens Date of approval: April 20, 2004 Paper: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. University Hospital Rotterdam, Dijkzigt, Rotterdam, The Netherlands. AIDS. 2003 Jul;17 Suppl 3:S55-61. Paper |
van der Ende ME, Schutten M, Osterhaus ADME. |
| I05515 | Defining the prognosis of HIV-1 infected patients treated with potent antiretroviral therapy Date of Approval: Oct 27, 2005 |
de Wolf F. |
| I07403 | Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy Date of Approval: Jan 16, 2003 Paper: Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. Van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM. HIV Med. 2004 Mar;5(2):74-81. Abstract |
van Leth F, Wit F, Reiss P, Schattenkerk JKME, van der Ende ME, Schneider MME, Mulder JW, Frissen PHJ, de Wolf F, Lange JMA. |
| I07303 | Tolerance, safety and efficacy of antiretroviral combination therapy in HIV-infected women Date of Approval: Jan 16, 2003 Paper: Nelfinavir and nevirapine side effects during pregnancy. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group. AIDS. 2005 May 20;19(8): 795-9. Paper Paper: Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects. Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5. |
van der Ende ME, Nellen FJ, Godfried MH, Boer K, Dieleman JP, de Wolf F, Schneider MME. |
| I10303 | TRIESTAN (TReatment Interruption in Early STArters - Netherlands) Date of Approval: Jan 19, 2006 Paper: Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400. Abstract Presentation: Treatment Interruption in Early Starters in the Netherlands (TRIESTAN): Successful for at Least 36 Weeks. Pogány K, van Valkengoed I, Kroon F, Prins J, Lange J, Brinkman K. At CROI February 2005 12th conference on retroviruses and opportunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.584, p.267. |
Brinkman K, Pogany K, Prins JM, Kroon FP, Wit F, Lange JMA. |
| I13018 | Efficacy of lamivudine compared to emtricitabine in nevirapine and efavirenz based antiretroviral therapy: an observational retrospective cohort study Date of approval: June 3, 2013 |
B. Rijnders, A. Verbon, C, Rokx, D. van de Vijver |
| I05548 | Incidence of HPV-related anogenital cancers in HIV-infected patients Date of approval: 2005 Paper: Gradually decreasing anal cancer incidence in the HIV+ population in the Netherlands after a decade of cART. Richel O, van der Zee RP, Smit C, de Vries HJ, Prins JM. Sex Health 2013 Nov;10(6):586. doi:10.1071/SHv10n6ab33. |
O. Richel |
| I07252 | Study on sexual behaviour among HIV infected homosexual men Date of approval: May 11, 2010 Collection of data from these men has now been incorporaed into the ACS protocols and will continue as part of the ACS; therefore, this project is closed. |
I. Stolte, A. Krol, M. Prins, A. van Eeden, M. Groot. |
| I05006 | Epidemiology and pathology of HIV coinfection with Hepatitis B and C Date of approval: Jan, 2005 |
J.E. Arends, I.M. Hoepelman, C.A.B. Boucher, C. Smit |
| I08044 | Primo SHM R5x4 HAART | M. Grijsen, M. Welkers |
| I12106 | Differences of HIV-1-infected children in the Netherlands from different countries of origin Date of approval: 2012 Paper: Country of Birth Does Not Influence Long-term Clinical, Virologic, and Immunological Outcome of HIV-Infected Children Living in the Netherlands: A Cohort Study Comparing Children Born in the Netherlands With Children Born in Sub-Saharan Africa. Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D. J Acquir Immune Defic Syndr. 2015 Feb 1; 68(2):178-185. Abstract. |
Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D |
| I13153 |
Factor associated with late diagnosis of HIV in the Netherlands Paper: Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort. Op de Coul EL, van Sighem A, Brinkman K, Benthem BH, Ende ME, Geerlings S, Reiss P; ATHENA national observational HIV cohort. BMJ Open. 2016 Jan 4;6(1):e009688 Abstract
|
E. Op de Coul, A. van SIghem, K. Brinkman, I. van der Ende, S. Geerlings |
| I10042 |
The use of nevirapine dose escalation in patients who switch from efavirenz to nevirapine (discontinued) |
D. Burger, M. Blonk, F. Wit, C. Smit, M. van Luin, L. Gelinck, H. Sprenger, P. Koopmans. |